Publications of Lars Nitschke

Search


Lars Nitschke on Google Scholar

5 Key Publications

Müller J, Nitschke L. (2014) The role of CD22 and Siglec-G in B-cell tolerance and autoimmune disease. Nat Rev Rheumatol. 10:422-8.

Schmitt H, Sell S, Koch J, Seefried M, Sonnewald S, Daniel C, Winkler TH, Nitschke L. (2016) Siglec-H protects from virus-triggered severe systemic autoimmunity. J Exp Med. 213:1627-44

Müller J, Obermeier I, Wöhner M, Brandl C, Mrotzek S, Angermüller S, Maity PC, Reth M, Nitschke L. (2013) CD22 ligand-binding and signaling domains reciprocally regulate B-cell Ca2+ signaling. Proc Natl Acad Sci U S A. 110:12402-7

Ackermann J, Radtke D, Maurberger, A, Winkler TH, Nitschke L (2011) Grb2 regulates Bcell maturation, B cell memory responses and inhibits B cell Ca2+ signalling. EMBO J. 30:1621-1633

Hoffmann A, Kerr S, Jellusova J, Zhang J, Weisel F, Wellmann U, Winkler TH, Kneitz B, Crocker PR, Nitschke L. (2007)  Siglec-G is a B1 cell-inhibitory receptor that controls expansion and calcium signaling of the B1 cell population. Nat Immunol. 8:695-704.


Primary Publications(since 2012)

Prescher H, Frank M, Gütgemann S, Kuhfeldt E, Schweizer A, Nitschke L, Watzl C, Brossmer R. (2017) Design, Synthesis, and Biological Evaluation of Small, High-Affinity Siglec-7 Ligands: Toward Novel Inhibitors of Cancer Immune Evasion. J Med Chem. 60: 941-956

Schmitt H, Sell S, Koch J, Seefried M, Sonnewald S, Daniel C, Winkler TH, Nitschke L. (2016) Siglec-H protects from virus-triggered severe systemic autoimmunity. J Exp Med. 213:1627-44

Radtke D, Lacher SM, Szumilas N, Sandrock L, Ackermann J, Nitschke L, Zinser E. (2016) Grb2 Is Important for T Cell Development, Th Cell Differentiation, and Induction of Experimental Autoimmune Encephalomyelitis. J Immunol. 196:2995-3005

Krzyzak L, Seitz C, Urbat A, Hutzler S, Ostalecki C, Gläsner J, Hiergeist A, Gessner A, Winkler TH, Steinkasserer A, Nitschke L. (2016) CD83 Modulates B Cell Activation and Germinal Center Responses. J Immunol. 196:3581-94

Özgör L, Brandl C, Shock A, Nitschke L. (2016) Epratuzumab modulates B-cell signaling without affecting B-cell numbers or B-cell functions in a mouse model with humanized CD22. Eur J Immunol. 46:2260-72

Gruber, S., Hendrikx, T., Tsiantoulas, D., Ozsvar-Kozma, M., Goderle, L., Mallat, Z., Witztum, J.L., Shiri-Sverdlov, R., Nitschke, L., and Binder, C.J. (2016). Sialic Acid-Binding Immunoglobulin-like Lectin G Promotes Atherosclerosis and Liver Inflammation by Suppressing the Protective Functions of B-1 Cells. Cell Rep 14, 2348-2361.

Gasparrini, F., Feest, C., Bruckbauer, A., Mattila, P.K., Muller, J., Nitschke, L., Bray, D., and Batista, F.D. (2016). Nanoscale organization and dynamics of the siglec CD22 cooperate with the cytoskeleton in restraining BCR signalling. EMBO J 35, 258-280.

Nitschke L. (2015) Siglec-G is a B-1 cell inhibitory receptor and also controls B cell tolerance. Ann N Y Acad Sci. 1362:117-21

Übelhart R, Hug E, Bach MP, Wossning T, Dühren-von Minden M, Horn AH, Tsiantoulas D, Kometani K, Kurosaki T, Binder CJ, Sticht H, Nitschke L, Reth M, Jumaa H. (2015) Responsiveness of B cells is regulated by the hinge region of IgD. Nat Immunol. 16:534-43

Ludwig J, Federico G, Prokosch S, Küblbeck G, Schmitt S, Klevenz A, Gröne HJ, Nitschke L, Arnold B. (2015) Dickkopf-3 acts as a modulator of B cell fate and function. J Immunol. 194:2624-34.

Müller, J., Lunz, B., Schwab, I., Acs, A., Nimmerjahn, F., Daniel, C., and Nitschke, L. (2015). Siglec-G deficiency leads to autoimmunity in aging C57BL/6 mice. J Immunol195,51-60.

Engels N, König LM, Schulze W, Radtke D, Vanshylla K, Lutz J, Winkler TH, Nitschke L, Wienands J. (2014) The immunoglobulin tail tyrosine motif upgrades memory-type BCRs by incorporating a Grb2-Btk signalling module. Nat Commun. 5:5456.

Nitschke L. (2014) CD22 and Siglec-G regulate inhibition of B-cell signaling by sialic acid ligand binding and control B-cell tolerance. Glycobiology. 24:807-17.

Luo W, Mayeux J, Gutierrez T, Russell L, Getahun A, Müller J, Tedder T, Parnes J, Rickert R, Nitschke L, Cambier J, Satterthwaite AB, Garrett-Sinha LA. (2014) A balance between B cell receptor and inhibitory receptor signaling controls plasma cell differentiation by maintaining optimal Ets1 levels. J Immunol. 2014 Jul 15;193(2):909-20.

Simonetti G, Bertilaccio MT, Rodriguez TV, Apollonio B, Dagklis A, Rocchi M, Innocenzi A, Casola S, Winkler TH, Nitschke L, Ponzoni M, Caligaris-Cappio F, Ghia P. (2014) SIGLEC-G deficiency increases susceptibility to develop B-cell lymphoproliferative disorders. Haematologica. 99:1356-64.

Prescher H, Schweizer A, Kuhfeldt E, Nitschke L, Brossmer R. (2014) Discovery of multifold modified sialosides as human CD22/Siglec-2 ligands with nanomolar activity on B-cells. ACS Chem Biol. 9:1444-50.

Hutzler S, Özgör L, Naito-Matsui Y, Kläsener K, Winkler TH, Reth M, Nitschke L. (2014) The ligand-binding domain of Siglec-G is crucial for its selective inhibitory function on B1 cells. J Immunol. 192:5406-14.

Müller J, Nitschke L. (2014) The role of CD22 and Siglec-G in B-cell tolerance and autoimmune disease. Nat Rev Rheumatol. 10:422-8.

Bökers S, Urbat A, Daniel C, Amann K, Smith KG, Espéli M, Nitschke L. (2014) Siglec-G deficiency leads to more severe collagen-induced arthritis and earlier onset of lupus-like symptoms in MRL/lpr mice. J Immunol. 192:2994-3002.

Niedzielska M, Bodendorfer B, Münch S, Eichner A, Derigs M, da Costa O, Schweizer A, Neff F, Nitschke L, Sparwasser T, Keyse SM, Lang R. (2014) Gene trap mice reveal an essential function of dual specificity phosphatase Dusp16/MKP-7 in perinatal survival and regulation of Toll-like receptor (TLR)-induced cytokine production. J Biol Chem. 289:2112-26.

Naito-Matsui Y, Takada S, Kano Y, Iyoda T, Sugai M, Shimizu A, Inaba K, Nitschke L, Tsubata T, Oka S, Kozutsumi Y, Takematsu H. (2014) Functional evaluation of activation-dependent alterations in the sialoglycan composition of T cells. J Biol Chem. 289:1564-79.

Dütting S, Vögtle T, Morowski M, Schiessl S, Schäfer CM, Watson SK, Hughes CE, Ackermann JA, Radtke D, Hermanns HM, Watson SP, Nitschke L, Nieswandt B. (2014) Growth factor receptor-bound protein 2 contributes to (hem)immunoreceptor tyrosine-based activation motif-mediated signaling in platelets. Circ Res.114:444-53.

Nitschke L. (2013) Suppressing the antibody response with Siglec ligands. N Engl J Med. 369:1373-4.

Puttur F, Arnold-Schrauf C, Lahl K, Solmaz G, Lindenberg M, Mayer CT, Gohmert M, Swallow M, van Helt C, Schmitt H, Nitschke L, Lambrecht BN, Lang R, Messerle M, Sparwasser T. (2013) Absence of Siglec-H in MCMV infection elevates interferon alpha production but does not enhance viral clearance. PLoS Pathog. 9(9):e1003648.

Müller J, Obermeier I, Wöhner M, Brandl C, Mrotzek S, Angermüller S, Maity PC, Reth M, Nitschke L. (2013) CD22 ligand-binding and signaling domains reciprocally regulate B-cell Ca2+ signaling. Proc Natl Acad Sci U S A. 110:12402-7.

Wöhner M, Born S, Nitschke L. (2012) Human CD22 cannot fully substitute murine CD22 functions in vivo, as shown in a new knockin mouse model. Eur J Immunol.42: 3009-18

Schwab I, Seeling M, Biburger M, Aschermann S, Nitschke L, Nimmerjahn F. (2012) B cells and CD22 are dispensable for the immediate antiinflammatory activity of intravenous immunoglobulins in vivo. Eur J Immunol. 42:3302-9

Walker JA, Hall AM, Kotsopoulou E, Espeli M, Nitschke L, Barker RN, Lyons PA, Smith KG. (2012) Increased red cell turnover in a line of CD22-deficient mice is caused by Gpi1c: a model for hereditary haemolytic anaemia. Eur J Immunol. 42:3212-22

Schweizer A, Wöhner M, Prescher H, Brossmer R, Nitschke L. (2012) Targeting of CD22-positive B-cell lymphoma cells by synthetic divalent sialic acid analogues. Eur J Immunol. 42:2792-802.